Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages

J. Szebeni, S. M. Wahl, M. Popovic, L. M. Wahl, S. Gartner, R. L. Fine, U. Skaleric, R. M. Friedmann, J. N. Weinstein

Research output: Contribution to journalArticle

41 Citations (Scopus)


Dipyridamole (DPM) is commonly used as a coronary vasodilator and inhibitor of platelet aggregation in the treatment of cardiovascular diseases. We report here that DPM potentiates the inhibitory effects of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-deoxycytidine against human immunodeficiency virus type 1 (HIV-1) in human monocyte-macrophages. At the same concentrations, DPM does not potentiate the toxic effects of AZT on these cells or on human bone marrow (granulocyte-monocyte) progenitor cells. Since monocyte-macrophage lineage cells appear to be the major reservoir for HIV-1 in vivo, these findings suggest the possibility of using DPM or its analogues in combination chemotherapy of HIV infections.

Original languageEnglish
Pages (from-to)3842-3846
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number10
Publication statusPublished - Jan 1 1989


ASJC Scopus subject areas

  • General

Cite this